mRNA-1365
- Generic Name
- mRNA-1365
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
Phase 1
Active, not recruiting
- Conditions
- Respiratory Syncytial VirusHuman Metapneumovirus
- Interventions
- First Posted Date
- 2023-02-24
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 310
- Registration Number
- NCT05743881
- Locations
- 🇺🇸
Los Angeles Children's Hospital, Los Angeles, California, United States
🇺🇸Palmetto Pediatrics, PA, North Charleston, South Carolina, United States
🇿🇦Family Centre for Research with Ubuntu (FAMCRU)- Tygerberg, Cape Town, Western Cape, South Africa
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath